Clinical Research Directory

INCLUSION CRITERIA: A volunteer must have met all of the following criteria: * Able and willing to complete the informed consent process. * 18 to 65 years of age. * HIV-1 infected. * On a stable antiretroviral regimen for greater than or equal to 3 months. * Available for clinical follow-up through the last study visit. * Based on history and examination, must be in general good health with no evidence of clinically significant lab abnormalities and without additional clinically significant medical conditions as per exclusion criteria. * Willing to maintain or establish a relationship with a primary health care provider for medical management of HIV infection while participating in the study. * Willing to have blood samples collected, stored indefinitely, and used for research purposes. * Able to provide proof of identity to the satisfaction of the study clinician completing the enrollment process. * Laboratory tests assessing individual's health will be conducted within 84 days prior to enrollment and values must meet the following criteria: 1. White blood cell count (WBC) 2,500-12,000/mm\^3; 2. WBC differential either within institutional normal range or accompanied by approval of the Principal Investigator (PI) or designee; 3. Platelets = 125,000-400,000/mm\^3; 4. Hemoglobin greater than or equal to 10.0 gm/dL; 5. Creatinine less than or equal to 1.25 x upper limit of normal (ULN); 6. Alanine aminotransferase (ALT) less than or equal to 1.1 x ULN; 7. Aspartate aminotransferase (AST) less than or equal to 1.1 x ULN; and, 8. Viral Load (VL) less than or equal to 50 copies/mL and a CD4 count greater than or equal to 300/mcL (microliter). Male-Specific Criteria: * Males must agree to use condoms for all sexual activity of any reproductive potential for 52 weeks after receiving the study product. Female-Specific Criteria: * If a woman is sexually active with a male partner and has no history of hysterectomy, tubal ligation or menopause, she must agree to use either a prescription birth control method or a barrier birth control method from the time of study enrollment through study Week 52, or to be monogamous with a partner who has had a vasectomy. * Negative beta-HCG (human chorionic gonadotropin) pregnancy test (urine or serum) on day of enrollment for women presumed to be of reproductive potential. EXCLUSION CRITERIA: A volunteer would have been excluded if one or more of the following conditions applied: * Previous receipt of monoclonal antibody whether licensed or investigational. * Previous receipt of gene therapy product. * Ongoing AIDS-related opportunistic infection (including oral thrush). * Active injection drug use or active drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements. * A titer of pre-existing antibodies to AAV8 capsid is greater than 1:90. * Weight \> 115 kg for Group 3 participants only. * History of a severe allergic reaction with generalized urticaria, angioedema or anaphylaxis within the 2 years prior to enrollment that has a reasonable risk of recurrence. * Bleeding disorder diagnosed by a doctor (e.g. factor deficiency, coagulopathy, or platelet disorder requiring special precautions) or significant bruising or bleeding difficulties with IM injections or blood draws. * Active liver disease such as chronic hepatitis. * Hypertension that is not well controlled by medication. * Woman who is breast-feeding or planning to become pregnant during the study participation. * Receipt of any investigational study agent within 28 days prior to enrollment. * Current infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). * Any other chronic or clinically significant medical condition that in the opinion of investigator would jeopardize the safety or rights of the volunteer, including, but not limited to: diabetes mellitus type I; OR clinically significant forms of asthma, autoimmune disease, psychiatric disorders, heart disease, or cancer.